Trials / Conditions / Sickle Cell Disease (SCD)

Sickle Cell Disease (SCD)

19 registered clinical trials studyying Sickle Cell Disease (SCD) — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE NCT07530965	University of Alabama at Birmingham	N/A
Not Yet Recruiting	Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopou NCT07488520	Swiss Tropical & Public Health Institute	Phase 4
Not Yet Recruiting	Megakaryocyte Heterogeneity in Sickle Cell Disease NCT06850337	Centre Hospitalier Universitaire de la Guadeloupe	—
Recruiting	Exploratory Study on Global Reflexology in Sickle Cell Disease NCT06619197	Hospices Civils de Lyon	N/A
Recruiting	Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease NCT06665997	University of Pennsylvania	Phase 4
Recruiting	Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient NCT06887907	University Hospital, Toulouse	—
Not Yet Recruiting	Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation NCT06619093	Hospices Civils de Lyon	—
Not Yet Recruiting	Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Ane NCT06761560	Yves Pastore	Phase 2 / Phase 3
Recruiting	Sickle Cell Kidney Biorepository NCT07064174	University of Texas Southwestern Medical Center	—
Recruiting	Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modify NCT06941389	University of Rochester	—
Terminated	Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cel NCT05565092	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	Risk Factors, Costs, and Impacts of ED Boarding NCT07532564	University of Maryland, Baltimore	—
Completed	An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients NCT04662931	Novartis Pharmaceuticals	Phase 4
Completed	Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and NCT04413539	Argo Sante	—
Completed	Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused NCT04053764	Novartis Pharmaceuticals	Phase 2
Active Not Recruiting	Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients NCT03814746	Novartis Pharmaceuticals	Phase 3
Completed	Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients NCT03474965	Novartis Pharmaceuticals	Phase 2
Completed	Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging NCT03478917	National Heart, Lung, and Blood Institute (NHLBI)	—
Completed	Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients Wi NCT03264989	Novartis Pharmaceuticals	Phase 2